valirx bioinnovation limited
valirx bioinnovation limited Company Information
Company Number
05834378
Website
www.valirx.comRegistered Address
stonebridge house, chelmsford road, hatfield heath, CM22 7BD
Industry
Research and experimental development on biotechnology
Telephone
442476796496
Next Accounts Due
September 2025
Group Structure
View All
Directors
Gerry Desler17 Years
Shareholders
valirx plc 100%
valirx bioinnovation limited Estimated Valuation
Pomanda estimates the enterprise value of VALIRX BIOINNOVATION LIMITED at £55.2k based on a Turnover of £54.4k and 1.01x industry multiple (adjusted for size and gross margin).
valirx bioinnovation limited Estimated Valuation
Pomanda estimates the enterprise value of VALIRX BIOINNOVATION LIMITED at £0 based on an EBITDA of £0 and a 4.16x industry multiple (adjusted for size and gross margin).
valirx bioinnovation limited Estimated Valuation
Pomanda estimates the enterprise value of VALIRX BIOINNOVATION LIMITED at £2.7m based on Net Assets of £5.3m and 0.51x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Valirx Bioinnovation Limited Overview
Valirx Bioinnovation Limited is a live company located in hatfield heath, CM22 7BD with a Companies House number of 05834378. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in June 2006, it's largest shareholder is valirx plc with a 100% stake. Valirx Bioinnovation Limited is a established, micro sized company, Pomanda has estimated its turnover at £54.4k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Valirx Bioinnovation Limited Health Check
Pomanda's financial health check has awarded Valirx Bioinnovation Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 4 areas for improvement. Company Health Check FAQs
1 Strong
1 Regular
4 Weak
Size
annual sales of £54.4k, make it smaller than the average company (£4.3m)
- Valirx Bioinnovation Limited
£4.3m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Valirx Bioinnovation Limited
- - Industry AVG
Production
with a gross margin of 27.6%, this company has a higher cost of product (54.4%)
- Valirx Bioinnovation Limited
54.4% - Industry AVG
Profitability
an operating margin of 0% make it more profitable than the average company (-10.7%)
- Valirx Bioinnovation Limited
-10.7% - Industry AVG
Employees
with 1 employees, this is below the industry average (53)
1 - Valirx Bioinnovation Limited
53 - Industry AVG
Pay Structure
on an average salary of £82k, the company has an equivalent pay structure (£82k)
- Valirx Bioinnovation Limited
£82k - Industry AVG
Efficiency
resulting in sales per employee of £54.4k, this is less efficient (£124.5k)
- Valirx Bioinnovation Limited
£124.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Valirx Bioinnovation Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Valirx Bioinnovation Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Valirx Bioinnovation Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Valirx Bioinnovation Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Valirx Bioinnovation Limited
- - Industry AVG
VALIRX BIOINNOVATION LIMITED financials
Valirx Bioinnovation Limited's latest turnover from December 2023 is estimated at £54.4 thousand and the company has net assets of £5.3 million. According to their latest financial statements, Valirx Bioinnovation Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Admin Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Profit | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Pre-Tax Profit | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -240,737 | |||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Profit After Tax | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -240,737 | |||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Retained Profit | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -240,737 | |||
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Number Of Employees | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
| EBITDA* | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 0 | 4,808,560 | 4,808,560 | 0 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 0 | 4,808,560 | 4,808,560 | 0 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 | 4,808,560 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 447,187 | 447,187 | 447,187 | 447,187 | 447,187 | 300,670 | 0 | 300,710 | 300,670 | 0 | 300,670 | 300,670 | 300,670 | 300,670 | 300,670 |
| Misc Debtors | 40 | 40 | 40 | 40 | 40 | 40 | 0 | 0 | 40 | 0 | 40 | 40 | 40 | 40 | 40 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 447,227 | 447,227 | 447,227 | 447,227 | 447,227 | 300,710 | 0 | 300,710 | 300,710 | 0 | 300,710 | 300,710 | 300,710 | 300,710 | 300,710 |
| total assets | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| net assets | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 |
| total shareholders funds | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,255,787 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 0 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 | 5,109,270 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 0 | 0 | 0 | 146,517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 | 0 | 146,517 | 300,710 | -300,710 | 0 | 300,710 | -300,710 | 0 | 0 | 0 | 0 | 300,710 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 0 | 0 | 0 | 0 | -300,710 | 0 | -300,710 | 0 | 0 | 0 | 0 | -300,710 | |||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 4,808,560 | -4,808,560 | 0 | 4,808,560 | -4,808,560 | 0 | 0 | 0 | 0 | 4,808,560 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| cash flow from financing | 0 | 0 | 0 | 0 | 5,109,270 | 0 | 5,109,270 | 0 | 0 | 0 | 0 | 5,350,007 | |||
| cash and cash equivalents | |||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
valirx bioinnovation limited Credit Report and Business Information
Valirx Bioinnovation Limited Competitor Analysis
Perform a competitor analysis for valirx bioinnovation limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in CM22 area or any other competitors across 12 key performance metrics.
valirx bioinnovation limited Ownership
VALIRX BIOINNOVATION LIMITED group structure
Valirx Bioinnovation Limited has 1 subsidiary company.
Ultimate parent company
VARIOUS
#0105055
2 parents
VALIRX BIOINNOVATION LIMITED
05834378
1 subsidiary
valirx bioinnovation limited directors
Valirx Bioinnovation Limited currently has 1 director, Mr Gerry Desler serving since Oct 2006.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Gerry Desler | England | 79 years | Oct 2006 | - | Director |
P&L
December 2023turnover
54.4k
0%
operating profit
0
0%
gross margin
27.6%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
5.3m
0%
total assets
5.3m
0%
cash
0
0%
net assets
Total assets minus all liabilities
valirx bioinnovation limited company details
company number
05834378
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
June 2006
age
18
incorporated
UK
accounts
Audit Exemption Subsidiary
ultimate parent company
previous names
valirx limited (October 2006)
last accounts submitted
December 2023
address
stonebridge house, chelmsford road, hatfield heath, CM22 7BD
accountant
ADLER SHINE LLP
auditor
-
valirx bioinnovation limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to valirx bioinnovation limited.
valirx bioinnovation limited Companies House Filings - See Documents
| date | description | view/download |
|---|
